Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 01/02/19 at 11:45am

Scandal dominated this week’s news after Sunrise Lee, a stripper turned Insys sales rep was alleged to have given a disreputable doctor a lap dance in an effort to persuade him to prescribe the potent opioid fentanyl to his patients. Meanwhile Vertex terminated COO Ian Smith over ‘personal behaviour’ while an Israeli biotech made the dubious claim that it had created a complete cure for cancer.

In other news, Health Secretary Matt Hancock said that patients would be able to pay the NHS to sequence their genes, as long as they shared their data. The story prompted fears of the creation of a two tiered system in Britain’s beloved NHS. Meanwhile Novartis warned of the impact of no-deal Brexit.

Check out the top ten most popular stories of this week!

10. People in England will be able to pay the NHS to sequence their genetic data, if they share it with scientists

The NHS will provide paid-for health reports, informing patients as to the likelihood that they will develop diseases such as Alzheimer’s or cancer, as long as those people share their data.

9. Opioid drugmaker Purdue Pharma inks deal with Alivio over non-opioid inflammation drug

Opioid drugmaker Purdue Pharma has entered into an agreement with inflammatory disease specialist Alivio Therapeutics for the development of the non-opioid treatment for interstitial cystitis/bladder pain syndrome, ALV-107.

8. Alexander Hardy returns to Genentech as new CEO

Genetech, the biotech subsidiary of Swiss firm Roche, has named its new CEO, revealing that Alexander Hardy will be returning to the company to lead its operations.

7. Vertex ousts COO Ian Smith over 'personal behaviour'

Boston-based firm Vertex Pharmaceuticals has fired Chief Operating Officer (COO) and interim Chief Financial Officer (CFO) Ian Smith. Smith’s termination, which is said to be unrelated to the company’s financial and business performance is effective immediately.

6. Roche pulls plug on Alzheimer's drug after Phase 3 failure

Roche has announced that it is to terminate two Phase 3 studies investigating the efficacy of its anti-beta-amyloid molecule crenezumab in the treatment of early sporadic Alzheimer’s disease (AD), after it became apparent that the drug was unlikely to meet its primary endpoint.

5. Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application

Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer.

4. Mylan's Wixela becomes first FDA-approved generic version of GSK's Advair inhaler

Mylan’s Wixela has become the first generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler to be approved in the US.

3. Novartis warns of huge impact of no-deal Brexit

Swiss pharmaceutical company Novartis has called on the British government to ‘ensure continuity of supply’ in the case of a ‘disorderly’ no-deal Brexit.

2. Stripper-turned-Insys sales rep gave lap dance to persuade doctor to prescribe fentanyl

A pharmaceutical executive working for Insys therapeutics has been accused of giving a doctor a lap dance in an effort to persuade him to prescribe a fentanyl spray to his patients.

1. Israeli biotech claims it has developed cure for cancer

An Israeli biotech has claimed that it has developed a complete cure for cancer.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches